A Virtual Reality Tour – The Role of Targeted Multiple Kinase Inhibitors in the Management of Advanced Hepatocellular Carcinoma

REGISTER NOW!
Already Registered?
SIGN IN

WEBCAST DATE

Saturday, January 18, 2020

8:00 AM Eastern    7:00 AM Central    6:00 AM Mountain    5:00 AM Pacific

PROGRAM FEATURES

• Virtual Reality videos included in presentation
• Case-based learning environment
• iPads provided to enhance learning experience
• Personalized poster portal

FACULTY

Thomas Cartwright, MD
Associate Professor of Medicine
University of Central Florida School of Medicine
Co-Chair US Oncology GI Research
Ocala, FL

Roshan Shrestha, MD, FAST, FAASLD
Medical Director of Liver Transplantation
Piedmont Transplant Institute
Clinical Professor of Medicine
Mercer University School of Medicine
Atlanta, GA

LEARNING OBJECTIVES

I. Hepatocellular Carcinoma: An Overview
  a. Epidemiology
    a. Risk factors
    b. Comorbid conditions
    c. Disease burden and effects on patient quality of life
  b. Disease pathophysiology
    a. Role of comorbid conditions in HCC pathophysiology
    b. Roles of tyrosine kinases in HCC pathophysiology
    c. Disease course

II. Management of HCC
  a. Diagnosis of HCC
    a. Screening recommendations
    b. Diagnostic criteria
    c. Imaging of HCC
    d. Staging of HCC
    e. Role of alpha-fetoprotein
  b. Standard of care treatment options
    a. Guideline recommendations

III. Therapeutic Options for the Treatment of Advanced HCC
  a. Approved agents for the treatment of patients with advanced HCC
    i. (VR Theme: mechanisms of action of multikinase inhibitors in the treatment of HCC)
    ii. Clinical trial efficacy and safety results
    iii. Emerging agents

IV. Individualizing the Sequencing of Care for Patients
  a. Analysis of patient-specific factors that affect outcomes, including treatment history, comorbidities, and age
  b. Role of newly approved agents in established treatment algorithms and clinical practice
  c. Consideration of patient preferences

V. Case studies

VI. Conclusions

VII. Questions and answers

LEARNING OBJECTIVES

After completing the educational activity, learners should be better able to:

• Review how the evolving understanding of HCC pathophysiology has informed new potential treatment targets
• Critically assess the efficacy and safety of established and investigational systemic and targeted therapies, as well as combination therapies, for patients with advanced HCC
• Develop individualized plans for the sequencing of treatment regimens for patients with advanced HCC based on patient-specific characteristics

TARGET AUDIENCE

This activity is designed to meet the educational needs of hepatologists, oncologists, interventional radiologists, and other members of the multidisciplinary oncology team (NPs, PAs, pharmacists) responsible for the care of patients with HCC.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
 

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 2.0 AMA Category 1 Credit(s)^TM.
 
Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with HCC.

CNE Credits: 2.0 ANCC Contact Hour(s)

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 2.0 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.